Australia's ReNerve gains on partnership to expand product portfolio
02/06/2025 02:10
** Biotech co ReNerve RNV.AX rises 4.8% to A$0.110; set for its steepest intraday pct rise since May 21 ** Firm enters partnership with Berkeley Biologics to develop two new types of tissue-based medical products ** YTD, RNV losses 37.1% (Reporting by Manasi Dasa in Bengaluru) ((Manasi.DasaSundeep@thomsonreuters.com;))
Recent news on Renerve
See all newsBrief: Renerve Says Positive FDA Feedback On Nervalign Nerve Guide Matrix
Brief: Renerve And Rmit Awarded A$499K Grant
Brief: ReNerve Posts Full-Year Loss Attributable Of A$5.6 Million
Brief: ReNerve Says Nervalign Nerve Cuff Receives CDSCO Marketing Approval In India
Australia's ReNerve rises on securing up to A$5 million funding facility